Innospec Reports First Quarter 2022 Financial Results
Innospec reported strong financial results for Q1 2022, with revenues of $472.4 million, up 39% from last year, and a 57% increase in operating income. GAAP EPS was $1.46, with adjusted non-GAAP EPS at $1.53. The gross margin remained stable despite inflationary pressures. The company announced an 11% dividend increase to 63 cents per share and commenced share repurchases. EBITDA rose 43% to $59 million. The performance was driven by significant sales growth across all business segments, although Oilfield Services faced challenges with shipment delays.
- Revenues increased by 39% to $472.4 million.
- Operating income rose by 57%, showcasing strong business performance.
- GAAP EPS increased to $1.46; adjusted non-GAAP EPS was $1.53, representing substantial growth.
- 11% increase in dividend to 63 cents per share, reflecting commitment to shareholder returns.
- Share repurchases initiated, enhancing shareholder value.
- Operational cash flow was negative due to increased working capital, amounting to $29 million used in operations.
- Oilfield Services segment experienced a decline in operating income due to shipment delays.
Strong contributions from all businesses with revenues up 39 percent and operating income up 57 percent
Gross margin in the expected range despite high inflationary and sustained supply chain pressures
Dividend increased by 11 percent; Share repurchases commenced
GAAP EPS of
ENGLEWOOD, Colo., May 03, 2022 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced its financial results for the first quarter ended March 31, 2022. The Company also announced the declaration of its semi-annual dividend of 63 cents per common share for the first half of 2022, representing an increase of 11 percent. This dividend will be paid on May 26, 2022, to shareholders of record on May 17, 2022.
Total revenues for the first quarter were
Results for this quarter include some special items, which are summarized in the table below. Excluding these items, adjusted non-GAAP EPS in the first quarter was
Due to strong sequential sales growth, cash generation for the quarter was impacted by an increase in working capital which resulted in cash used in operations of
EBITDA, income before income taxes and net income excluding special items, and related per-share amounts, are non-GAAP financial measures that are defined and reconciled with GAAP results herein and in the schedules below.
Quarter ended March 31, 2022 | Quarter ended March 31, 2021 | |||||||||||||||||
(in millions, except share and per share data) | Income before income taxes | Net income | Diluted EPS | Income before income taxes | Net income | Diluted EPS | ||||||||||||
Reported GAAP amounts | $ | 48.2 | $ | 36.5 | $ | 1.46 | $ | 30.8 | $ | 23.4 | $ | 0.94 | ||||||
Amortization of acquired intangible assets | 3.6 | 2.9 | 0.12 | 3.7 | 3.0 | 0.12 | ||||||||||||
Foreign currency exchange gains | (3.1 | ) | (2.3 | ) | (0.09 | ) | (1.6 | ) | (1.2 | ) | (0.05 | ) | ||||||
Legacy costs of closed operations | 1.1 | 0.9 | 0.04 | 0.9 | 0.7 | 0.03 | ||||||||||||
Acquisition related costs | - | - | - | 0.8 | 0.6 | 0.02 | ||||||||||||
1.6 | 1.5 | 0.07 | 3.8 | 3.1 | 0.12 | |||||||||||||
Adjusted non-GAAP amounts | $ | 49.8 | $ | 38.0 | $ | 1.53 | $ | 34.6 | $ | 26.5 | $ | 1.06 |
Commenting on the first quarter results, Patrick S. Williams, President and Chief Executive Officer, said,
“This was an excellent quarter for Innospec. Despite sustained inflationary and supply-chain pressures, we achieved 39 percent sales growth, maintained gross margins and delivered a 57 percent increase in operating income. We anticipate strong demand to continue in all end-markets, and in coordination with our customers we are managing additional price actions as required to offset inflationary impacts. Managing ongoing supply and logistical challenges will continue to be a key focus for our global team to meet customer requirements and ensure product availability.
In Performance Chemicals, strong sales and margins drove a 38 percent increase in operating income over the prior year. The majority of this growth came from personal care which now comprises over 75 percent of Performance Chemicals operating income. We believe strong demand continues to support our outlook for high single-digit volume growth.
In Fuel Specialties, operating income grew by 49 percent over the prior year as recovering volumes and continued price action drove strong quarterly sales. Gross margins improved significantly over the fourth quarter and returned to the lower end of our target 32 to 35 percent range. We expect gross margins to remain on the lower end of our target range until cost inflation moderates. We anticipate further gross margin improvement when inflation slows, and activity increases in areas like jet travel that still remain significantly below pre-pandemic levels.
In Oilfield Services, sales grew by 19 percent sequentially. However, shipment delays led to a sequential quarter decline in operating income. We expect sequential operating income and margin improvement to resume in the coming quarters.”
In Performance Chemicals, revenues of
Revenues in Fuel Specialties were
Revenues in Oilfield Services were
Corporate costs for the quarter were
The effective tax rate for the quarter was 24.3 percent compared to 24.0 percent in the same period last year.
Due to strong sequential sales growth, net cash used in operating activities after capital expenditure was
Mr. Williams concluded,
“We are very pleased with our start to the year. Volume growth and disciplined price management drove strong sales and double-digit operating income increases in Performance Chemicals and Fuel Specialties. Excellent results in these two businesses more than offset the lagging results in Oilfield Services. We expect Oilfield Services to resume its sequential operating income improvement in the coming quarters. In all three businesses, end-market demand continues to be strong.
We believe that our debt-free balance sheet, broad mix of daily-use consumable products and relentless focus on customer service positions us well for continued growth in all our businesses.
We repurchased
Use of Non-GAAP Financial Measures
The information presented in this press release includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise EBITDA, income before income taxes excluding special items, net income excluding special items and related per share amounts together with net cash. EBITDA is net income per our consolidated financial statements adjusted for the exclusion of charges for interest expense, net, income taxes, depreciation, and amortization. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of amortization of acquired intangible assets, foreign currency exchange gains, legacy costs of closed operations and acquisition related costs. Net cash is cash and cash equivalents less total debt. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP financial measures are provided herein and in the schedules below. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company’s performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. In addition, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company’s performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and adjusted net income and EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income) to allocate resources and evaluate the performance of the Company’s operations. Management believes the most directly comparable GAAP financial measure is GAAP net income and has provided a reconciliation of EBITDA and net income excluding special items, and related per share amounts, to GAAP net income herein and in the schedules below.
About Innospec Inc.
Innospec Inc. is an international specialty chemicals company with approximately 1,900 employees in 24 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil and gas exploration and production industry.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, including, the effects of the COVID-19 pandemic, such as its duration, its unknown long-term economic impact, measures taken by governmental authorities to address it, the rise of variants, the effectiveness, acceptance and distributions of COVID-19 vaccines and the effects of any sanctions, export restrictions, supply chain disruptions or increased economic uncertainty related to the ongoing conflict between Russia and Ukraine and the manner in which the pandemic and/or such conflict may precipitate or exacerbate other risks and/or uncertainties, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2021 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Corbin Barnes
Innospec Inc.
+44-151-355-3611
corbin.barnes@innospecinc.com
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Schedule 1
(in millions, except share and per share data) | Three Months Ended March 31 | |||||
2022 | 2021 | |||||
Net sales | $ | 472.4 | $ | 339.6 | ||
Cost of goods sold | (333.1 | ) | (238.8 | ) | ||
Gross profit | 139.3 | 100.8 | ||||
Operating expenses: | ||||||
Selling, general and administrative | (84.9 | ) | (63.6 | ) | ||
Research and development | (10.1 | ) | (9.0 | ) | ||
Total operating expenses | (95.0 | ) | (72.6 | ) | ||
Operating income | 44.3 | 28.2 | ||||
Other income, net | 4.3 | 3.0 | ||||
Interest expense, net | (0.4 | ) | (0.4 | ) | ||
Income before income taxes | 48.2 | 30.8 | ||||
Income taxes | (11.7 | ) | (7.4 | ) | ||
Net income | $ | 36.5 | $ | 23.4 | ||
Earnings per share: | ||||||
Basic | $ | 1.47 | $ | 0.95 | ||
Diluted | $ | 1.46 | $ | 0.94 | ||
Weighted average shares outstanding (in thousands): | ||||||
Basic | 24,791 | 24,601 | ||||
Diluted | 24,956 | 24,840 |
INNOSPEC INC. AND SUBSIDIARIES
Schedule 2A
SEGMENTAL ANALYSIS OF RESULTS | Three Months Ended March 31 | |||||
(in millions) | 2022 | 2021 | ||||
Net sales: | ||||||
Performance Chemicals | $ | 167.1 | $ | 125.9 | ||
Fuel Specialties | 191.8 | 139.3 | ||||
Oilfield Services | 113.5 | 74.4 | ||||
472.4 | 339.6 | |||||
Gross profit: | ||||||
Performance Chemicals | 40.8 | 31.4 | ||||
Fuel Specialties | 60.7 | 44.9 | ||||
Oilfield Services | 37.8 | 24.5 | ||||
139.3 | 100.8 | |||||
Operating income: | ||||||
Performance Chemicals | 25.3 | 18.3 | ||||
Fuel Specialties | 35.5 | 23.8 | ||||
Oilfield Services | 2.5 | 1.2 | ||||
Corporate costs | (19.0 | ) | (15.1 | ) | ||
Total operating income | $ | 44.3 | $ | 28.2 |
Schedule 2B
NON-GAAP MEASURES | Three Months Ended March 31 | |||||
(in millions) | 2022 | 2021 | ||||
Net income | $ | 36.5 | $ | 23.4 | ||
Interest expense, net | 0.4 | 0.4 | ||||
Income taxes | 11.7 | 7.4 | ||||
Depreciation and amortization: | ||||||
Performance Chemicals | 5.4 | 5.4 | ||||
Fuel Specialties | 1.6 | 1.3 | ||||
Oilfield Services | 2.9 | 3.1 | ||||
Corporate costs | 0.5 | 0.4 | ||||
EBITDA | 59.0 | 41.4 | ||||
EBITDA: | ||||||
Performance Chemicals | 30.7 | 23.7 | ||||
Fuel Specialties | 37.1 | 25.1 | ||||
Oilfield Services | 5.4 | 4.3 | ||||
Corporate costs | (18.5 | ) | (14.7 | ) | ||
54.7 | 38.4 | |||||
Other income, net | 4.3 | 3.0 | ||||
EBITDA | $ | 59.0 | $ | 41.4 |
EBITDA by segment includes operating income relating to the segments, excluding depreciation and amortization.
Schedule 3
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions) | March 31, 2022 | December 31, 2021 | ||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ | 105.6 | $ | 141.8 |
Trade and other accounts receivable | 337.7 | 284.5 | ||
Inventories | 308.2 | 277.6 | ||
Prepaid expenses | 17.2 | 18.0 | ||
Prepaid income taxes | 9.5 | 5.8 | ||
Other current assets | 0.4 | 0.4 | ||
Total current assets | 778.6 | 728.1 | ||
Net property, plant and equipment | 213.7 | 214.4 | ||
Operating lease right-of-use assets | 42.3 | 35.4 | ||
Goodwill | 362.0 | 364.3 | ||
Other intangible assets | 53.0 | 57.5 | ||
Deferred tax assets | 6.2 | 6.4 | ||
Pension asset | 160.8 | 159.8 | ||
Other non-current assets | 7.2 | 5.0 | ||
Total assets | $ | 1,623.8 | $ | 1,570.9 |
Liabilities and Stockholders’ Equity | ||||
Current liabilities: | ||||
Accounts payable | $ | 161.8 | $ | 148.7 |
Accrued liabilities | 156.5 | 166.5 | ||
Current portion of finance leases | - | 0.1 | ||
Current portion of operating lease liabilities | 14.1 | 12.4 | ||
Current portion of plant closure provisions | 6.2 | 5.2 | ||
Current portion of accrued income taxes | 13.7 | 3.7 | ||
Total current liabilities | 352.3 | 336.6 | ||
Operating lease liabilities, net of current portion | 28.3 | 23.1 | ||
Plant closure provisions, net of current portion | 50.1 | 51.3 | ||
Accrued income taxes, net of current portion | 27.8 | 30.6 | ||
Unrecognized tax benefits | 16.3 | 16.3 | ||
Deferred tax liabilities | 61.3 | 60.8 | ||
Pension liabilities and post-employment benefits | 17.4 | 17.8 | ||
Other non-current liabilities | 1.4 | 1.4 | ||
Equity | 1,068.9 | 1,033.0 | ||
Total liabilities and equity | $ | 1,623.8 | $ | 1,570.9 |
Schedule 4
INNOSPEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in millions) | Three Months Ended March 31 | |||||
2022 | 2021 | |||||
Cash Flows from Operating Activities | ||||||
Net income | $ | 36.5 | $ | 23.4 | ||
Adjustments to reconcile net income to cash provided by operating activities: | ||||||
Depreciation and amortization | 10.5 | 10.3 | ||||
Deferred taxes | 0.9 | 0.1 | ||||
Non-cash movements on defined benefit pension plans | (0.7 | ) | (0.8 | ) | ||
Stock option compensation | 1.7 | 1.6 | ||||
Changes in working capital | (79.3 | ) | (13.6 | ) | ||
Movements in accrued income taxes | 3.4 | 3.7 | ||||
Movements in plant closure provisions | - | (0.2 | ) | |||
Movements in other assets and liabilities | (2.0 | ) | (1.8 | ) | ||
Net cash (used in)/provided by operating activities | (29.0 | ) | 22.7 | |||
Cash Flows from Investing Activities | ||||||
Capital expenditures | (8.4 | ) | (10.3 | ) | ||
Net cash used in investing activities | (8.4 | ) | (10.3 | ) | ||
Cash Flows from Financing Activities | ||||||
Repayment of finance leases | (0.1 | ) | (0.2 | ) | ||
Issue of treasury stock | 1.9 | 0.5 | ||||
Repurchase of common stock | (0.9 | ) | (0.6 | ) | ||
Net cash provided by/(used in) financing activities | 0.9 | (0.3 | ) | |||
Effect of foreign currency exchange rate changes on cash | 0.3 | (0.4 | ) | |||
Net change in cash and cash equivalents | (36.2 | ) | 11.7 | |||
Cash and cash equivalents at beginning of period | 141.8 | 105.3 | ||||
Cash and cash equivalents at end of period | $ | 105.6 | $ | 117.0 |
Amortization of deferred finance costs of
FAQ
What were Innospec's financial results for Q1 2022?
What is Innospec's GAAP EPS for Q1 2022?
What is the adjusted non-GAAP EPS for Innospec?
When will Innospec's increased dividend be paid?